



NEWS RELEASE

## Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026

2026-05-11

SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (NASDAQ: OMER) today announced that it will issue its financial results for the first quarter 2026 on Wednesday, May 13, 2026 after market close. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss recent developments and highlights as well as the Company's financial results.

### Conference Call Details and Webcast Link Instructions

To access the live webcast, please click [here](#) or visit the "**Upcoming Events**" section of the Investor Relations page of Omeros' website.

A replay of the call will be available for 90 days in the "**Archived Events**" section of the Investor Relations page of Omeros' website.

As Omeros continues to transition to a new earnings call platform (hosted by Q4 Inc.), please allow extra time to log in prior to the start of the call.

### About Omeros Corporation

Omeros is an innovative biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for both large-market and orphan indications, with a focus on complement-mediated diseases, cancers, and addictive or compulsive disorders. Omeros' lead complement inhibitor YARTEMLEA® (narsoplimab-wuug), which targets the lectin pathway's effector enzyme MASP-2, is FDA-approved and commercially available in the U.S. for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) in adult and pediatric patients aged two years and older. A marketing authorization application seeking approval of YARTEMLEA for TA-TMA is currently under review at the European Medicines Agency. OMS1029, Omeros' long-acting MASP-2 inhibitor, has successfully completed Phase 1 clinical trials.

Under a recently announced asset purchase and licensing agreement, Novo Nordisk acquired global rights to zaltenibart (formerly OMS906), an inhibitor of MASP-3, the alternative pathway's key activator, which is in clinical development for PNH and other alternative pathway indications, along with associated intellectual property and related assets. Omeros' pipeline also includes OMS527, a phosphodiesterase 7 inhibitor in clinical development for cocaine use disorder, which is fully funded by the National Institute on Drug Abuse, and a growing portfolio of novel recombinant antibodies targeting multidrug-resistant organisms and novel molecular and cellular therapeutic programs for oncology. For more information about Omeros and its programs, visit [www.omeros.com](http://www.omeros.com).

Jennifer Cook Williams

Cook Williams Communications, Inc.

Investor and Media Relations

**IR@omeros.com**

Source: Omeros Corporation